+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Tolrestat in the primary prevention of diabetic neuropathy



Tolrestat in the primary prevention of diabetic neuropathy



Diabetes Care 18(4): 536-541



To compare the effects of tolrestat and placebo in patients with subclinical diabetic neuropathy. Non-insulin-dependent diabetes mellitus (NIDDM) patients with early involvement of the autonomic nervous system were identified by only one pathological (outside the 99% confidence interval of the normal population) squatting test (vagal or sympathetic). Fifty-seven patients entered a randomized, placebo-controlled, double-blind, parallel 52-week study of tolrestat at a dose of 200 mg/day. Cardiovascular reflex tests (squatting vagal and sympathetic tests, pressure gain, deep breathing, lying-to-standing, Valsalva maneuver, and orthostatic hypertension), vibration thresholds, tendon reflexes, and muscle strength were assessed throughout the study. At 12 months, nerve function significantly improved in patients receiving tolrestat and deteriorated in patients taking placebo. At baseline, the squatting vagal test was normal in 16 patients in the tolrestat group and in 15 patients in the placebo group. At 12 months, 25 patients taking tolrestat had a normalized squatting test, but only 6 patients taking placebo did (P = 0.02). Vibration perception threshold improved by a value of 6 +/- 3 V in the tolrestat group (P < 0.001) and deteriorated by a value of 3 +/- 1.8 V (P < 0.001) in the placebo group. Tolrestat may be useful in the primary prevention of diabetic neuropathy.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 044819017

Download citation: RISBibTeXText

PMID: 7497865

DOI: 10.2337/diacare.18.4.536


Related references

A multicentre trial of the aldose-reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy. North European Tolrestat Study Group. Diabete and Metabolisme 18(1): 14-20, 1992

Effect of Tolrestat on oesophageal transit time and cholecystic motility in type 2 diabetic patients with asymptomatic diabetic neuropathy. Diabete and Metabolisme 21(5): 360-364, 1995

Safety of Tolrestat in Diabetic Neuropathy. Clinical Drug Investigation 10(4): 235-241, 1995

Tolrestat in diabetic autonomic neuropathy. Diabetologia 38(Suppl. 1): A237, 1995

Treatment of severe diabetic neuropathy with tolrestat. Anesthesiology 79(3A): A801, 1993

Tolrestat in the therapy of diabetic peripheral neuropathy: is this drug really useful?. La Clinica Terapeutica 146(12): 793-799, 1995

Safety of Tolrestat in Diabetic Neuropathy: The Italian Multicentre Surveillance Study. Clinical Drug Investigation 10(4): 235-241, 1995

Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial. Annals of Internal Medicine 118(1): 7-11, 1993

Effect of tolrestat on heart rate variability in patients with diabetic autonomic neuropathy. Diabetologia 39(Suppl. 1): A256, 1996

A double blind controlled study on the effect of tolrestat on diabetic autonomic neuropathy. Diabetologia 34(Suppl. 2): A152, 1991

Effect of tolrestat on circadian variation of heart rate in patients with diabetic autonomic neuropathy. Diabetologia 42(Suppl. 1): A300, 1999

A multicenter trial of the aldose reductase inhibitor tolrestat in patient with symptomatic diabetic neuropathy. Diabetologia 33(7): 431-437, 1990

The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. A meta-analysis of individual patient data. Diabetes Care 19(10): 1091-1096, 1996

Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: Effect on nerve function. Journal of Diabetes and its Complications 7(3): 170-178, 1993

Effect of tolrestat on circadian variation of heart rate variability in patients with diabetic autonomic neuropathy. Diabetes 48(Suppl. 1): A151, 1999